[CAS NO. 1638250-96-0]  ETC-159

Ships within Stock Price Qty Total
$0.00
$0.00
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [1638250-96-0]

Catalog
HY-18988
Brand
MCE
CAS
1638250-96-0

DESCRIPTION [1638250-96-0]

Overview

MDLMFCD29472267
Molecular Weight391.38
Molecular FormulaC19H17N7O3
SMILESO=C(NC1=CC=C(C2=CC=CC=C2)N=N1)CN3C=NC4=C3C(N(C)C(N4C)=O)=O

For research use only. We do not sell to patients.


Summary

ETC-159 (ETC-1922159) is a potent, orally available PORCN inhibitor. ETC-159 inhibits β-catenin reporter activity with an IC 50 of 2.9 nM.


IC50 & Target

IC50: 2.9 nM (β-catenin) [1]


In Vitro

ETC-159 blocks the secretion and activity of all Wnts. ETC-159 has robust activity in multiple cancer models driven by high Wnt signaling. ETC-159 is highly efficacious in molecularly defined colorectal cancers (CRCs) with R-spondin translocations [1]

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


In Vivo

ETC-159 inhibits mouse PORCN with an IC 50 of 18.1 nM, whereas the IC50 for Xenopus Porcn is approximately four fold higher (70 nM). ETC-159 is remarkably effective in treating RSPO-translocation bearing colorectal cancer (CRC) patient-derived xenografts. ETC-159 exhibits good oral pharmacokinetics in mice allowing preclinical evaluation via oral administration. After a single oral dose of 5 mg/kg, ETC-159 is rapidly absorbed into the blood with a T max of ~0.5 h and oral bioavailability of 100% [1] .

MCE has not independently confirmed the accuracy of these methods. They are for reference only.


Clinical Trial

NCT Number Sponsor Condition Start Date Phase
NCT02521844 EDDC (Experimental Drug Development Centre), A*STAR Research Entities|PPD
Solid Tumors
October 2015 Phase 1

Appearance

Solid


Shipping

Room temperature in continental US; may vary elsewhere.


Storage

Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL ( 127.75 mM ; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.5551 mL 12.7753 mL 25.5506 mL
5 mM 0.5110 mL 2.5551 mL 5.1101 mL
10 mM 0.2555 mL 1.2775 mL 2.5551 mL
* Please refer to the solubility information to select the appropriate solvent.
In Vivo:
  • 1.

    Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline

    Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

  • 2.

    Add each solvent one by one: 10% DMSO >> 90% corn oil

    Solubility: ≥ 2.5 mg/mL (6.39 mM); Clear solution

* All of the co-solvents are available by MCE.